Evidence map›Paper›PMID 40769954›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2025

Modulating Antimicrobial Activity and Structure of the Peptide Esc(1-21) via Site-Specific Isopeptide Bond Formation.

Bruno Casciaro, Daniel Ben Hur, Daniela Roversi, Carlo Vetrano, Edo Kiper, Giacomo Cappella, Federico Carneri, Eeva Tortellini, Lorenzo Stella, Neta Regev-Rudzki and 2 more

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Modulating Antimicrobial Activity and Structure of the Peptide Esc(1-21) via Site-Specific Isopeptide Bond Formation.Journal of peptide science : an official publication of the European Peptide Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bruno CasciaroLaboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0003-1295-1084
Daniel Ben HurDepartment of Biomolecular Sciences, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.ORCID https://orcid.org/0000-0002-5679-5696
Daniela RoversiDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Rome, Italy.ORCID https://orcid.org/0009-0006-2140-2465
Carlo VetranoLaboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0009-0003-5181-7301
Edo KiperDepartment of Biomolecular Sciences, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.ORCID https://orcid.org/0000-0002-2376-7170
Giacomo CappellaLaboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0009-0000-6180-166X
Federico CarneriDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Rome, Italy.ORCID https://orcid.org/0009-0006-0344-7192
Eeva TortelliniLaboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-3110-5193
Lorenzo StellaDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Rome, Italy.ORCID https://orcid.org/0000-0002-5489-7381
Neta Regev-RudzkiDepartment of Biomolecular Sciences, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.ORCID https://orcid.org/0000-0001-7252-0193
Yechiel ShaiDepartment of Biomolecular Sciences, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.ORCID https://orcid.org/0000-0002-8588-5586
Maria Luisa MangoniLaboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-5991-5868

Funding

BINA - the translational research and innovation unit of the Weizmann InstituteDr. Barry Sherman Institute for Medicinal ChemistryEuropean Union - NextGenerationEU ECS 00000024Israeli Ministry of Science and Technology 3-14316Israel Science Foundation (ISF) 1944/20Ministero dell'Istruzione, dell'Università e della Ricerca PRIN 2020833Y75_005Ministero dell'Istruzione, dell'Università e della Ricerca PRIN2022-2022XFFTH5PNRR Missione 4 Componente 2 Investimento 1.5Rome Technopole CUPB83C22002820006Sapienza Università di Roma RG124190CBD34B9D
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) represent valid alternatives to conventional antibiotics primarily due to their mechanism of action, which consists of cytoplasmic membrane disruption. However, their clinical application is often limited by cytotoxicity at high concentrations and low intrinsic biostability. To address these limitations, various biochemical approaches have been explored. In recent years, the frog-skin derived AMP Esc(1-21) has been extensively characterized for its potent antimicrobial activity, especially against Gram-negative bacteria, both in vitro and in vivo. In this study, we designed and synthesized novel Esc(1-21) analogs in which a single isopeptide bond was introduced in place of a conventional peptide bond at specific positions within the sequence. The resulting five analogs were evaluated for their (i) chemical and structural properties, (ii) resistance to proteolytic degradation, (iii) antimicrobial and antibiofilm activities, (iv) hemolytic and cytotoxic effects, and (v) ability to perturb bacterial cytoplasmic membranes. Among these, Esc(1-21)ε20 showed the most promising features, maintaining antimicrobial and antibiofilm activities comparable to those of the parent peptide while exhibiting lower cytotoxicity towards eukaryotic cells at higher concentrations and greater resistance to enzymatic degradation. These findings highlight Esc(1-21)ε20 as an attractive lead candidate for the development of new antibiotic therapeutics.

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesAnimalsAnuraBiofilmsGram-Negative BacteriaHemolysisHumansMicrobial Sensitivity TestsStructure-Activity RelationshipAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptides

Identifiers

PMID40769954
PMCPMC12328261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.